Table 2.

Cases of de-novo SCLC with EGFR mutations

	Age (years)	Sex	Smoking history (pack years)	Tumour histology	EGFR mutation in SCLC initial sample	Treatment with TKI	Response to TKI	EGFR amplification or protein expression in SCLC
Shiao and colleagues²⁹
Patient 1	54	F	0	SCLC	Exon 19 deletion	Gefitinib	Progressed	Unknown
Patient 2	63	M	Heavy smoker	SCLC	Exon 19 deletion	No	NA	Unknown
Tatematsu and colleagues³⁰
Patient 1	36	F	0	Combined SCLC/adenocarcinoma	Leu858Arg	Gefitinib	Partial response	Amplification of EGFR in adenocarcinoma only
Patient 2	81	M	40	SCLC	Gly719Ala	Gefitinib	Partial response	Amplification of EGFR in SCLC
Patient 3	69	M	30	Combined SCLC/adenocarcinoma	Leu858Arg	No	NA	Amplification of EGFR in adenocarcinoma only
Patient 4	89	F	2·5	SCLC	Leu858Arg	No	NA	No EGFR amplification
Patient 5	65	M	67·5	Combined SCLC/adenocarcinoma	Exon 19 deletion	No	NA	Amplification of EGFR in adenocarcinoma only
Araki, Okamoto, and colleagues³¹,³²	72	F	0	SCLC	Exon 19 deletion	Gefitinib	Partial response	Immunohistochemistry positive for EGFR protein expression
Norkowski and colleagues²⁶
Patient 1	62	M	0	Combined SCLC/adenocarcinoma	Gly719Ala and exon 21 deletion found in both SCLC and adenocarcinoma	No	NA	Unknown
Patient 2	66	F	80	Combined SCLC/adenocarcinoma	Exon 19 deletion in adenocarcinoma component only	No	NA	NA
Patient 3	65	F	45	Synchronous SCLC and adenocarcinoma	Leu858Arg in adenocarcinoma component only	No	NA	NA
Fukui and colleagues³³	62	F	0	Combined SCLC/adenocarcinoma	Leu858Arg in both SCLC and adenocarcinoma	No	NA	Unknown
Lu and colleagues³⁴
Patient 1	62	F	0	Combined SCLC/adenocarcinoma	Exon 19 deletion in both SCLC and adenocarcinoma	No	NA	Unknown
Patient 2	61	M	Smoker	Combined SCLC/squamous-cell carcinoma	Exon 19 deletion in SCLC	No	NA	Unknown
Kurahara and colleagues³⁵	65	F	0	SCLC	Leu858Arg	No	NA	Unknown

Rows are individual patients. SCLC=small-cell lung cancer. TKI=tyrosine kinase inhibitor. NA=not applicable.